Skip to main content
Propanc Biopharma, Inc. logo

Propanc Biopharma, Inc. — Investor Relations & Filings

Ticker · PPCB ISIN · US74346N4043 LEI · 549300Q3HY827FNV8Y56 US Professional, scientific and technical activities
Open in API
Filings indexed 412 across all filing types
Latest filing 2019-03-07 Capital/Financing Update
Country US United States of America
Listing US PPCB

About Propanc Biopharma, Inc.

https://www.propanc.com/

Propanc Biopharma, Inc. is a clinical-stage company developing cancer treatments focused on preventing tumor recurrence and metastasis. Its lead candidate, PRP, is a pancreatic proenzyme formulation designed to target and eradicate cancer stem cells. The therapeutic approach aims to suppress tumor progression by controlling cancer cell migration, inhibiting the formation of tumor blood vessels, and inducing cell death. The company's primary focus is on developing long-term therapies for patients with solid tumors, such as pancreatic cancer.

Recent filings

Filing Released Lang Actions
Capital/Financing Update 2019
Capital/Financing Update Classification · 100% confidence The document is a prospectus filed under Rule 424(b)(3) related to the resale of common stock by a selling stockholder pursuant to an Equity Purchase Agreement. It includes detailed information about the offering, selling stockholder, plan of distribution, risk factors, business description, management discussion and analysis, and financial statements index. The document is clearly a registration and offering prospectus for securities, which is a type of capital raising and financing update. It is not an annual report, earnings release, or any other report type. The presence of terms like 'prospectus', 'offering', 'selling stockholder', 'plan of distribution', and the description of shares being offered for resale under an equity line confirms this is a Capital/Financing Update filing.
2019-03-07 English
Regulatory Filings 2019
Regulatory Filings Classification · 95% confidence The document is a letter from Propanc Biopharma, Inc. to the SEC requesting acceleration of the effective date of a Registration Statement on Form S-1. It is a formal correspondence related to a securities registration process, specifically under the Securities Act of 1933. The document does not contain financial statements, audit information, or detailed report content. It is a regulatory communication about the timing of a filing becoming effective, not the filing itself or a financial report. The document length is short (1592 characters), and it is clearly a regulatory filing related to the registration process. Therefore, it fits best under Regulatory Filings (RNS).
2019-03-05 English
Regulatory Filings 2019
Regulatory Filings
2019-03-05 English
Capital/Financing Update 2019
Capital/Financing Update Classification · 95% confidence The document is a Form S-1 Registration Statement filed with the U.S. Securities and Exchange Commission. It is a registration statement under the Securities Act of 1933 for Propanc Biopharma, Inc. The text includes details about the offering of common stock, the selling stockholder, the plan of distribution, risk factors, business description, management discussion and analysis, and financial statements index. This type of filing is used for initial public offerings or other securities registrations and is not an annual report, earnings release, or other types of filings listed. The document is a registration statement prospectus, which fits best under the category of Capital/Financing Update (CAP) as it relates to company fundraising and securities offering activities.
2019-02-25 English
Capital/Financing Update 2019
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 25, 2019, by Propanc Biopharma, Inc. It reports the entry into a material definitive agreement, specifically an Equity Purchase Agreement and a Registration Rights Agreement related to a financing transaction. The document details the terms of the financing, including share purchase rights, conditions, and obligations. It also references termination of a prior agreement and unregistered sales of equity securities. The document is a current report on material events and transactions, not a full financial report, earnings release, or management discussion. It is an update on capital raising activities and agreements, fitting the category of Capital/Financing Update (CAP). The document length is over 10,000 characters and contains substantive detail about the financing transaction, not just an announcement or summary, so it is not a Regulatory Filing (RNS) or Report Publication Announcement (RPA). Therefore, the appropriate classification is CAP with high confidence.
2019-02-25 English
Interim / Quarterly Report 2019
Interim / Quarterly Report Q2 2019
2019-02-14 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.